Q-omics provides the consensus-scored NFKBIZ profile across patient tissues and cancer cell-line models. NFKBIZ expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NFKBIZ is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, NFKBIZ RNA expression shows 19,697 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where NFKBIZ shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NFKBIZ — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NFKBIZ survival associations across molecular data types. NFKBIZ RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NFKBIZ RNA expression–survival associations across cancer types. High NFKBIZ expression shows unfavorable associations in KIRC, LGG, UVM and GBM, but favorable associations in BLCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NFKBIZ RNA expression.
This table summarizes NFKBIZ tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NFKBIZ. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NFKBIZ shows lower tumor expression in KICH, BLCA, UCEC, LUSC, BRCA and LUAD. The KICH box plot shows higher NFKBIZ RNA expression in normal versus tumor tissue (log2 FC = −2.591, t-test p < 0.001).
This table shows molecular features associated with NFKBIZ in patient tissues and cancer cell lines. In patient samples, NFKBIZ shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NFKBIZ RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
